{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-22-009406","form_type":"8-K","ticker":"PLX","cik":"0001006281","company_name":"Protalix BioTherapeutics, Inc.","filed_at":"2022-05-26T23:59:59+00:00","discovered_at":"2026-05-14T18:03:59.256858+00:00","generated_at":"2026-06-25T06:35:53.736413+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"confidence":"medium","headline":"Protalix announces five poster presentations at Fabry Disease conference","bullets":["Posters cover pegunigalsidase alfa data from BALANCE, BRIDGE, BRIGHT, and extension studies.","Conference is the 7th Update on Fabry Disease in Würzburg, Germany, May 29-31, 2022.","Posters and abstracts will be posted on Protalix's website under Investors/Presentations.","Data include 24-month renal function results from Phase III BALANCE study.","No specific efficacy or safety numbers were disclosed in the press release."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-22-009406","json":"https://secwatch.observer/filing/0001558370-22-009406.json","markdown":"https://secwatch.observer/filing/0001558370-22-009406.md","text":"https://secwatch.observer/filing/0001558370-22-009406.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1006281/000155837022009406/0001558370-22-009406-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1006281/000155837022009406/plx-20220526x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-25T06:35:53.736413+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}